Sagent Pharmaceuticals has introduced a folic acid derivative therapy, designed to treat megaloblastic anemias patients who are not responding to oral therapy.
The new Leucovorin Calcium for Injection is indicated for rescue after high-dose methotrexate therapy in osteosarcoma, diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists.
In addition, the therapy is used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
The therapy features the PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors, according to the company.
Sagent Pharmaceuticals president, chief executive officer and board chairman Jeffrey Yordon said, "Leucovorin, which has consistently been on both the American Society of Health System Pharmacists and Food and Drug Administration lists of drug shortages, is one of the first products which we will launch from our supply agreement with Zydus Cadila."
